Neoadjuvant carboplatin and docetaxel in locally advanced triple negative breast cancer: A Hispanic trial.

e12554Background: To evaluate the impact on efficacy and safety of combination of carboplatin plus docetaxel as neoadjuvant chemotherapy (NACT) for patients with locally advanced triple-negative breast cancer (TNBC), and explore an optimal regimen for TNBC in a Hispanic Cohort. The primary endpoint of the study was pathologic complete response (pCR), with secondary endpoints including clinical response and safety of the combination. Methods: Patients with biopsy confirmed pathological diagnosis of locally advanced invasive breast cancer, triple negative by immunohistochemistry, and with indication for NACT were eligible in this study. A total of thirty five patients (n = 35 ) were enrolled from January 2013 to November 2015 with stage II to III TNBC. Received doxorubicin plus cyclophosphamide once every 3 weeks for four cycles followed by docetaxel 75 mg/m(2) every three weeks for 4 cycles with concurrent carboplatin (area under curve 6) once every 3 weeks for four cycles. Effects of adding these agents o...